KPV

At a glance

---

What is KPV?

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH) — meaning it corresponds to the last three amino acids (positions 11-13) of that hormone: Lysine, Proline, and Valine.^[4]

Alpha-MSH is a 13-amino-acid neuropeptide with well-established roles in pigmentation, energy balance, and inflammation. Researchers in the late 1990s discovered that when they systematically tested fragments of alpha-MSH, the tiny C-terminal tripeptide KPV retained the parent hormone's full anti-inflammatory activity — despite being only three amino acids long and lacking the sequence needed to bind melanocortin receptors.^[1]

This was a surprising finding. Most peptides need a minimum sequence length to have biological activity. KPV challenged that assumption by showing potent NF-kB inhibition at just three amino acids. It's one of the smallest bioactive peptides known.

The melanocortin connection

KPV comes from the same biological family as several other well-known peptides:

• Alpha-MSH (the parent hormone) — regulates pigmentation, appetite, and inflammation
• PT-141 / Bremelanotide — a melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder
• Melanotan II — an unregulated melanocortin agonist used for tanning

The key difference: KPV does not bind melanocortin receptors. It doesn't cause pigmentation changes or sexual effects. Its anti-inflammatory activity works through a completely different mechanism — direct inhibition of NF-kB signaling inside the cell.^[8]

---

How it works

KPV's primary mechanism is inhibition of NF-kB, the master transcription factor that drives inflammatory gene expression. When NF-kB is activated, it triggers the production of pro-inflammatory cytokines like TNF-alpha, IL-1beta, and IL-6. KPV blocks this process at multiple levels.^[4]

What makes KPV unusual is how it reaches NF-kB. Because it's so small, it can be actively transported into cells through the PepT1 peptide transporter — a protein normally responsible for absorbing dietary peptides in the intestine. During inflammation, PepT1 expression increases in both intestinal cells and immune cells, effectively creating a delivery channel for KPV directly into the cells driving inflammation.^[5]

Detailed mechanism (for advanced readers)

KPV's anti-inflammatory mechanism operates through at least two distinct pathways:

• IkB stabilization: KPV prevents degradation of IkB-alpha, the inhibitory protein that sequesters NF-kB in the cytoplasm. By stabilizing IkB, KPV keeps NF-kB trapped in its inactive form, preventing nuclear translocation and subsequent inflammatory gene transcription.^[1]
• Direct nuclear import blockade: KPV has been shown to enter the nucleus itself and competitively block the interaction between importin-alpha3 and the p65/RelA subunit of NF-kB. This prevents p65 from being imported into the nucleus even if IkB is degraded. This dual-layer inhibition is unusual and may explain KPV's potency at low concentrations.^[8]
• PepT1-mediated uptake: The human peptide transporter 1 (hPepT1) actively transports KPV into intestinal epithelial cells and macrophages. PepT1 is upregulated during intestinal inflammation, creating a self-targeting delivery mechanism — KPV is preferentially taken up by the cells most actively involved in inflammatory signaling.^[5]
• Melanocortin receptor independence: Unlike full-length alpha-MSH, KPV lacks the His-Phe-Arg-Trp pharmacophore required for melanocortin receptor binding. Its anti-inflammatory effects persist in cells lacking MC1R and in MC1R-mutant mice, confirming a receptor-independent mechanism.^[6]
• Downstream effects: NF-kB inhibition results in decreased production of TNF-alpha, IL-1beta, IL-6, IL-8, and other pro-inflammatory mediators. KPV also suppresses MAPK/ERK signaling and reduces adhesion molecule expression.^[4]

How it differs from related compounds: Unlike BPC-157 (which works primarily through angiogenesis and growth factor signaling), KPV centers on direct transcriptional inhibition of inflammatory pathways. Unlike full-length alpha-MSH or PT-141, KPV does not activate melanocortin receptors and has no pigmentation or sexual function effects.

---

What the research says

KPV has never been tested in a single human clinical trial. Every piece of evidence we have comes from mice or cell cultures. The preclinical data is genuinely interesting — but "interesting in mice" and "works in humans" are separated by a chasm that most drug candidates never cross.

Research timeline

KPV's research history is shorter and more focused than many peptides, centered primarily on gut inflammation:

Animal studies

The preclinical literature for KPV is focused primarily on gut inflammation. Unlike BPC-157 with its 100+ studies across many organ systems, KPV research is narrower but comes from multiple independent groups:

Key findings by area

• Colitis / IBD (strongest evidence area): Oral KPV significantly reduced the severity of both DSS-induced and TNBS-induced colitis in mice, decreasing body weight loss, MPO activity, histological inflammation, and pro-inflammatory cytokine expression.^[5] This was independently confirmed by Kannengiesser et al. using DSS colitis and CD45RBhi transfer colitis models.^[6]
• Colitis-associated cancer: In a mouse model, KPV reduced colitis-associated tumorigenesis via PepT1-mediated delivery. Tumor number, size, and intestinal inflammation were all significantly decreased.^[10]
• Targeted drug delivery: Nanoparticle-encapsulated KPV in polysaccharide hydrogels reduced mouse colitis at concentrations 12,000-fold lower than free KPV, suggesting that advanced delivery could make very low doses therapeutically effective.^[7][11]
• Bronchial inflammation: In-vitro studies in human bronchial epithelial cells showed KPV suppresses NF-kB signaling and inflammatory cytokine production through a receptor-independent nuclear mechanism.^[8]
• Skin inflammation: KPV protected human keratinocytes from fine-dust-induced apoptosis and inflammation in a 2025 in-vitro study, with effects mediated through MAPK/NF-kB pathway modulation.^[12]
• Antimicrobial activity: Alpha-MSH and its C-terminal fragments including KPV show in-vitro antimicrobial activity against Staphylococcus aureus and Candida albicans.^[9]

---

What the evidence shows

People come to KPV primarily for gut health and anti-inflammatory benefits. Here's what the published research actually supports:

---

Safety & side effects

What research shows

There is no human safety data for KPV. This is not a situation where safety data is "limited" — it is completely absent. No clinical trial, case report, or pharmacovigilance system has ever documented what happens when a human takes KPV.

In preclinical studies, KPV has not shown overt toxicity in mouse colitis models at the doses used. The Dalmasso 2008 and Kannengiesser 2008 studies did not report significant adverse effects in treated animals.^[5][6]

Community-reported side effects

Among people who have used KPV outside of clinical settings, commonly discussed effects include:

• Mild nausea (more common with oral use)
• Injection-site redness or irritation (with subcutaneous use)
• Fatigue
• Headache

These are anecdotal reports from online communities, not from controlled studies. They should not be treated as safety data.

What we don't know

Theoretical considerations

Potential concerns (based on mechanism of action, not clinical data):

• Immune suppression: KPV inhibits NF-kB, a central inflammatory pathway. Chronic NF-kB suppression could theoretically impair immune defense against infections or tumors.
• Pregnancy and breastfeeding: No data of any kind. Should be considered contraindicated.
• Autoimmune conditions: While NF-kB inhibition could theoretically benefit autoimmune inflammation, uncontrolled immunomodulation carries risks.
• Drug interactions: No formal interaction studies. Theoretical interactions with immunosuppressants, anti-inflammatory drugs, or other NF-kB-targeting therapies.

Potential advantages of small size:

• At just 3 amino acids, KPV is unlikely to generate an immune (antibody) response
• Small peptides are generally less likely to accumulate in tissues
• The PepT1 transport mechanism provides a characterized route of cellular entry

These are theoretical considerations only — they do not constitute safety evidence.

---

How people use it

KPV is most commonly discussed in the context of gut health and general anti-inflammatory purposes. Here's what the landscape of use looks like — with important caveats about the total absence of clinical validation.

Administration routes

• Oral capsule (most discussed): KPV's small size and PepT1-mediated transport provide a theoretical basis for oral use, especially for gut-targeted effects. This is the only route with preclinical support from mouse colitis studies.
• Subcutaneous injection: Used in community practice for systemic anti-inflammatory effects. No clinical data supports this route.
• Topical: Emerging use in skincare contexts. One in-vitro study supports anti-inflammatory effects on keratinocytes, but no clinical skin studies exist.

Common stacking context

In community practice, KPV is often discussed alongside other peptides:

• KPV + BPC-157 — a gut-focused combination pairing KPV's NF-kB inhibition with BPC-157's tissue repair properties. No controlled studies support this combination.
• KPV + Thymosin Alpha-1 — discussed for immune modulation. Purely anecdotal.

All stacking protocols are community-derived and have not been studied in any controlled setting.

If you plan to reconstitute peptides, see our reconstitution guide for safety-first preparation instructions.

---

Legal & regulatory status

As of March 2026:

FDA status

KPV is not FDA-approved for any indication. In September 2023, the FDA classified it as a Category 2 bulk drug substance — meaning the agency determined there was insufficient evidence that it is safe for human use. Under this classification, compounding pharmacies are prohibited from using it.

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 Category 2 peptides would be reclassified to Category 1, restoring legal compounding access with a physician prescription. KPV is expected to be among those reclassified.

WADA / Anti-doping status

KPV is not explicitly named on the WADA Prohibited List. However, as a non-approved substance, it would likely fall under Section S0 (Non-Approved Substances), which prohibits any pharmacological substance not addressed by other sections of the list and not currently approved for human therapeutic use. Athletes should assume KPV is prohibited.

International status

KPV is not approved for clinical use in any country. It is available as a research chemical in most jurisdictions.

---

How KPV compares

To put KPV's evidence base in context, here's how it compares to BPC-157 (another popular gut-health peptide) and a fully approved drug:

The three-way comparison makes the evidence gap stark. Even BPC-157 — which itself has minimal human evidence — has three small human studies and 100+ animal publications. KPV has zero human data and a fraction of the animal literature. Semaglutide, a fully approved drug, illustrates what a complete evidence base looks like.

This doesn't mean KPV doesn't work. The preclinical data is genuinely interesting. But "interesting preclinical data" is the starting line for drug development, not the finish line — and KPV hasn't even entered human testing yet.

---

Related content

Guide

How to Reconstitute Peptides

A clear, safety-first guide to preparing lyophilized peptides. Essential reading if you're working with any injectable peptide.

News

First BPC-157 RCT

The first rigorous human trial for BPC-157 — relevant context for gut health peptide research.

Tool

Reconstitution Calculator

Calculate exact syringe units for KPV preparation.

---

References

1. [1]

   Lipton JM, Zhao H, Ichiyama T, Barsh GS, Catania A. “Mechanisms of antiinflammatory action of alpha-MSH peptides. In vivo and in vitro evidence.” Ann N Y Acad Sci. 1999. 885:173–182 DOI PubMedReview

   Foundational review establishing alpha-MSH/KPV anti-inflammatory mechanisms including NF-kB modulation.

2. [2]

   Luger TA, Scholzen TE, Brzoska T, Bohm M. “New insights into the functions of alpha-MSH and related peptides in the immune system.” Ann N Y Acad Sci. 2003. 994:133–140 DOI PubMedReview
3. [3]

   Luger TA, Brzoska T. “alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.” Ann Rheum Dis. 2007. 66(Suppl 3):iii52–iii55 DOI PubMedReview

   Proposes alpha-MSH derived peptides including KPV as a new drug class for inflammatory diseases.

4. [4]

   Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. “Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.” Endocr Rev. 2008. 29(5):581–602 DOI PubMedReview

   Definitive review in a high-impact journal. Establishes KPV as the minimal anti-inflammatory fragment of alpha-MSH.

5. [5]

   Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology. 2008. 134(1):166–178 DOI PubMedAnimal study

   Landmark study in a top-tier GI journal. First demonstration that oral KPV reduces colitis via PepT1 transport in mice.

6. [6]

   Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.” Inflamm Bowel Dis. 2008. 14(3):324–331 DOI PubMedAnimal study

   Independent confirmation from the Munster group (separate from Merlin lab). Used two IBD models and demonstrated MC1R-independent effects.

7. [7]

   Laroui H, Dalmasso G, Nguyen HTT, Yan Y, Sitaraman SV, Merlin D. “Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.” Gastroenterology. 2010. 138(3):843–853 DOI PubMedAnimal study

   KPV nanoparticle delivery at 12,000-fold lower doses than free solution with equivalent efficacy. Same research group as Dalmasso 2008.

8. [8]

   Land SC. “Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.” Int J Physiol Pathophysiol Pharmacol. 2012. 4(2):59–73 PubMedIn vitro

   First to demonstrate KPV enters the nucleus and directly blocks NF-kB p65 nuclear import. In vitro study using human bronchial cells.

9. [9]

   Singh M, Mukhopadhyay K. “Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide.” Biomed Res Int. 2014. 2014:874610 DOI PubMedReview
10. [10]

    Viennois E, Ingersoll SA, Ayyadurai S, Zhao Y, Wang L, Zhang M, Han MK, Garg P, Xiao B, Merlin D. “Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.” Cell Mol Gastroenterol Hepatol. 2016. 2(3):340–357 DOI PubMedAnimal study

    Extends colitis work to cancer prevention. KPV reduced colitis-associated tumorigenesis via PepT1 in mice.

11. [11]

    Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. “Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis.” Mol Ther. 2017. 25(7):1628–1640 DOI PubMedAnimal study

    Most advanced targeted delivery study for KPV. HA-functionalized nanoparticles with superior efficacy in mouse UC model.

12. [12]

    Lee S, et al.. “Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kB pathway.” Biochem Pharmacol. 2025. DOIIn vitro

    Recent in-vitro study in human keratinocytes and 3D skin models. Confirms MAPK/NF-kB pathway modulation.

---